Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316440 | 1.00 | CHRNA7 (0.44) | CHRNA7HTR2CCHRNB2CHRNA4KCNH2 | |
| SCHEMBL2641453 | 1.00 | CHRNA7 (0.44) | CHRNA7HTR2CCHRNB2CHRNA4KCNH2 | |
| Hydrochloric Acid SCHEMBL29369063 | 0.99 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4KCNH2 | |
| SCHEMBL4308400 | 0.89 | HTR2C (0.53) | HTR2CKCNH2 | |
| SCHEMBL4317284 | 0.89 | HTR2C (0.53) | HTR2CKCNH2 | |
| SCHEMBL4320148 | 0.89 | HTR2C (0.53) | HTR2CKCNH2 | |
| SCHEMBL4314743 | 0.88 | HTR2C (0.44) | HTR2CCHRNB2CHRNA4 | |
| SCHEMBL4313298 | 0.88 | HTR2C (0.39) | HTR2CCHRNB2CHRNA4 | |
| SCHEMBL4308561 | 0.88 | CHRNA7 (0.47) | CHRNA7KCNH2 | |
| SCHEMBL7474070 | 0.85 | CHRNB2 (0.44) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015001359-A1 | DRUG COMBINATION AND ITS USE IN THERAPY OF OBESITY | PROXIMAGEN LIMITED (GB) | 2015-01-08 | — | — | WO | claimed |
| WO-2015001357-A2 | DRUG COMBINATION AND ITS USE IN THERAPY | PROXIMAGEN LIMITED (GB) | 2015-01-08 | — | — | WO | claimed |
| WO-2015001358-A1 | DRUG COMBINATION AND ITS USE IN THERAPY OF OBESITY AND TYPE II DIABETES | PROXIMAGEN LIMITED (GB) | 2015-01-08 | — | — | WO | claimed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| WO-2015001357-A3 | DRUG COMBINATION AND ITS USE IN THERAPY OF OBESITY | PROXIMAGEN LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015001358-A1 | DRUG COMBINATION AND ITS USE IN THERAPY OF OBESITY AND TYPE II DIABETES | PROXIMAGEN LIMITED (GB) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001359-A1 | DRUG COMBINATION AND ITS USE IN THERAPY OF OBESITY | PROXIMAGEN LIMITED (GB) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001357-A2 | DRUG COMBINATION AND ITS USE IN THERAPY | PROXIMAGEN LIMITED (GB) | 2015-01-08 | — | — | WO | disclosed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| EP-1301476-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2002008178-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | CHRNA7 109/4885HTR2C 1/4885CHRNB2 294/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | CHRNA7 48/4885HTR2C 1/4885CHRNB2 28/4885 |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | HTR6, HTR5A, HTR2C | CHRNA7 174/4885HTR2C 3/4885CHRNB2 263/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | CHRNA7 179/4885HTR2C 1/4885CHRNB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.